Announced details
Achondroplasia (ACH), skeletal formation disorders and skeletal dysplasia
The Company's Phase 2 clinical trial results will be presented orally at the ISDS International Conference. No capital or personnel relationship is disclosed.
An international organization established in Zurich, Switzerland, in 1999 to promote scientific progress in the fields of skeletal formation disorders and skeletal dysplasia. It covers pharmacological, genetic, biochemical and medical research, drug development, and clinical research relating to diseases including achondroplasia (ACH). It holds its annual general meeting every 2 years.
Sick Kids Peter Gilgan Centre for Research and Learning, Toronto, Canada
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Information on the International Skeletal Dysplasia Society (ISDS) conference (https://www.isds.ch/index.php?page=isds-2026-meeting)
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol (anti-FGF2 aptamer) |
| Counterparty | International Skeletal Dysplasia Society（ISDS） |
| Counterparty overview | An international organization established in Zurich, Switzerland, in 1999 to promote scientific progress in the fields of skeletal formation disorders and skeletal dysplasia. It covers pharmacological, genetic, biochemical and medical research, drug development, and clinical research relating to diseases including achondroplasia (ACH). It holds its annual general meeting every 2 years. |
| Relationship with the Company | The Company's Phase 2 clinical trial results will be presented orally at the ISDS International Conference. No capital or personnel relationship is disclosed. |
| Launch date | 28 August 2026 (scheduled presentation date) |
| Applicable area | Achondroplasia (ACH), skeletal formation disorders and skeletal dysplasia |
| Location | Sick Kids Peter Gilgan Centre for Research and Learning, Toronto, Canada |
| Source | Information on the International Skeletal Dysplasia Society (ISDS) conference (https://www.isds.ch/index.php?page=isds-2026-meeting) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company believes that its efforts in nonclinical and clinical trials were recognized in being given the opportunity to present at the ISDS International Conference.